Author:
Rajput S. J.,Vanavi P. J.
Abstract
Abstract
Background
Tuberculosis is an infection that has high mortality rate in human as well as in animals if it remains unattained for long time. Scientists are always desirous to discover new molecules against Mycobacterium tuberculosis; one of them is bedaquiline which was recently approved to treat multidrug resistance TB. During the clinical study of new molecule stability and impurity are the key aspects to develop formulation. Stability issues in bulk drug are dangerous to drug safety and needs careful attention in formulation development. Bedaquiline stability study was completed with reversed-phase high-performance liquid chromatography (HPLC) and utilized in degradation kinetic study of bedaquiline in aqueous condition under different pH, temperature, and concentrations of degradant.
Results
Linearity was obtained in 50.0-250.0μg/ml, correlation coefficient, and regression line equation were 0.998 and Y=18528x + 7E+06 respectively. Intraday, inter day precision, and repeatability RSD were less than 2.0%. Average recovery in accuracy study was more than 98.0% showed that good recovery was obtained. Degradation kinetics parameters like activation energy (Ea), half-life (t50), rate constant (k), and shelf life (t90) were calculated under different condition for bedaquiline. Entropy and enthalpy of reaction was studied to gather knowledge about energy of system.
Conclusion
The result explained that bedaquiline degradation was pH-dependant, as increase in concentration of degradant and temperature, there was increase in degradation rate of bedaquiline. Bedaquiline was stable in neutral aqueous condition and at lower temperatures, shows that drug is hydrophobic in nature. Kinetic data showed that bedaquiline followed first order kinetics in acidic and alkaline pH.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. WHO (2014) Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis, Available Via. https://www.ncbi.nlm.nih.gov/books/NBK247434/ Accessed 13 Dec 2019.
2. Chahine EB, Karaoui LR, Mansour H (2014) Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann. Pharmacother 48(1):107–115. https://doi.org/10.1177/1060028013504087
3. Rombouts JA, Veenboer RMP, Villellas C (2016) Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues. RSC Adv 6(110):708–716
4. Alffenar JWC. And Bolhuis M.(2015).Determination of bedaquiline in human serum using liquid chromatography- tandem mass spectroscopy, Antimicrob Agent Chemother,59(9):5675-5680.
5. Momin M, Rangnekar B, Das S (2018) Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation. J Liquid Chromatogr Relat Technol 41(8):415–421
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献